KDM5B contributes to DPN via regulating SIRT3-mediated mitochondrial glucose and lipid metabolism. KDM5B inhibition may be an effective intervention for DPN (Diabetic Medicine)
Diabetes News
Tag: lipid
New insights into the role of empagliflozin on diabetic renal tubular lipid accumulation
EMPA inhibited the AGEs-RAGE pathway, thereby alleviating diabetic renal tubular cholesterol accumulation (Diabetology & Metabolic Syndrome)
Joint 30-year HbA1c and lipid trajectories and mortality in type 1 diabetes
These results suggest there is a subgroup with type 1 diabetes who, despite poor glycemic control, has a relatively good prognosis, perhaps related to good Non-HDLc (Diabetes Research and Clinical Practice)
Effect of blood lipid variability on mortality in patients with type 2 diabetes: a large single-center cohort study
Blood lipid variability except for triglyceride variability was associated with all-cause and cardiovascular mortality in patients with type 2 diabetes (Cardiovascular Diabetology)
Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
Tirzepatide reduces body weight and improves glycemic control and uniquely modulates metabolites associated with T2D risk and metabolic dysregulation in a direction consistent with improved metabolic health (Journal of Clinical Endocrinology & Metabolism)
Glycemic and lipid variability for predicting complications and mortality in diabetes mellitus using machine learning
Raised variability in HbA1c and lipid parameters are associated with an elevated risk in both diabetic complications and all-cause mortality. The association between hypoglycemic frequency, baseline NLR, and both HbA1c and lipid variability implicate a role for inflammation in mediating adverse outcomes in diabetes, but this should be explored further in future studies (BMC Endocrine Disorders)
Lipid Profile in Indian Patients With Type 2 Diabetes: The Scope for Atherosclerotic Cardiovascular Disease Risk Reduction
In South Indian patients with type 2 diabetes and fair glycemic control, high LDL cholesterol is the predominant lipid abnormality. There remains a huge potential for ASCVD risk reduction in this population if the knowledge practice gap is addressed (Diabetes Spectrum)
Lipid‐lowering medication is associated with decreased risk of diabetic retinopathy and the need for treatment in patients with type 2 diabetes
In a population of patients with type 2 diabetes with a variety of risk profiles, use of lipid‐lowering medication reduced the risk of DR and thus the risks involved in treatment with laser photocoagulation and vitrectomy (Diabetes, Obesity and Metabolism)
Lipids: A Suitable Therapeutic Target in Diabetic Neuropathy?
Future research should concentrate on targeting lipids with one or more aggressive interventions specifically in patients with DM2 whose DPN is detectable but whose progression can still be largely prevented (Journal of Diabetes Research)
Cardiovascular disease: risk assessment and reduction, including lipid modification
This guideline covers the assessment and care of adults who are at risk of or who have cardiovascular disease (CVD), such as heart disease and stroke. It aims to help healthcare professionals identify people who are at risk of cardiovascular problems. including people with type 1 or type 2 diabetes, or chronic kidney disease (NICE)
Targeting Adipose Tissue Lipid Metabolism to Improve Glucose Metabolism in Cardiometabolic Disease
This review will discuss recent advances in our understanding of classical lipolysis and lipophagy in adipocyte lipid metabolism under normal and pathological conditions (EMJ)
Glycosmedia is also available as an App: